Feb 10, 2021
Cipher Pharmaceuticals Enters into Co-Promotion Agreement with Verity Pharmaceuticals Inc.
Jan 15, 2021
Cipher Pharmaceuticals Receives Arbitration Award on Trulance®
Oct 08, 2020
Cipher Pharmaceuticals Reports Voting Results for the Election of Directors
Aug 12, 2020
Cipher Pharmaceuticals Reports Second Quarter 2020 Financial Results
Jul 02, 2020
Cipher Pharmaceuticals Appoints New Chief Financial Officer
Apr 20, 2020
Cipher Pharmaceuticals Receives Positive Ruling on Binding Arbitration with Upsher-Smith Laboratories
Jan 20, 2020
Cipher Pharmaceuticals Receives Notice of Termination from Bausch
Nov 07, 2019
Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results
Oct 24, 2019
Notice of Cipher Pharmaceuticals Q3 2019 Conference Call
Jul 30, 2019
Notice of Cipher Pharmaceuticals Q2 2019 Conference Call
May 01, 2019
Notice of Cipher Pharmaceuticals Q1 2019 Conference Call
Mar 20, 2019
Cipher Pharmaceuticals Announces Change to Management Team
Mar 15, 2019
Notice of Cipher Pharmaceuticals Q4 2018 Conference Call
Dec 05, 2018
Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018
Nov 07, 2018
Cipher Pharmaceuticals Reports Q3 2018 Results
Oct 24, 2018
Cipher Pharmaceuticals Announces Canadian Launch of Brinavess® (vernakalant hydrochloride)
Sep 18, 2018
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
Aug 10, 2018
Cipher Pharmaceuticals Reports Q2 2018 Results
Jul 23, 2018
Notice of Cipher Pharmaceuticals Q2 2018 Conference Call
Jun 06, 2018
Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs